InDevR develops the VaxArray platform, a versatile multiplexed microarray technology that recognizes and quantifies antigens, antibodies and nucleic acids, including mRNA. The company provides analytical test kits for CQA and QC testing of vaccines and biotherapeutics. It plans to use new capital to support commercial expansion and to develop new reagent kits for the VaxArray platform. VaxArray has been shown to provide high specificity and sensitivity for mRNA CQA/QC testing while eliminating the need to extract mRNA from lipid nanoparticles. The company has formed a strategic partnership with bioMérieux tied to distribution and product support. InDevR is based in Boulder, CO. InDevR, led by CEO and co-founder Dr. Kathy Rowlen, develops and commercializes analytical tools for biologic process development and vaccine manufacturing monitoring. Its product lines include the VaxArray® Influenza vaccine potency testing system, a multiplexed immunoassay, and the Cypher One analyzer for automated imaging and interpretation of hemagglutination and hemagglutination inhibition assays. The company has a history of non-dilutive funding, including a $14.7M BARDA contract to develop a high-information-content influenza diagnostic and a recent investment from the Bill & Melinda Gates Foundation to advance measles and rubella vaccine characterization. InDevR intends to use the new funds to conduct research and development and to build out its global commercial enterprise. The company focuses on life-science tool-based product lines aimed at improving vaccine process optimization and manufacturing.

Total raised

$16M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2023